Stearyl Alcohol Galactosidase Sorafenib Modified Liposomes And Targeting Of Mouse Liver

ObjectiveThis paper is stearyl alcohol (SA) galactosidase synthesis, structure identification, separation and purification, as well as with its modification of sorafenib (ST) liposome formulation design optimization, manufacturing process and target the liver in mice study anisotropic, with the target index (TI) of the change of stearyl alcohol as a guide galactosidase targeting molecules on the role of mouse liver.MethodIn this experiment,stearyl alcohol as the basic framework of guidance molecules, one end through a series of galactose synthesized soluble stearyl alcohol at one end of amphiphilic molecules oriented galactosidase (18-Gal), with its fat-soluble preparation Insert one end of the liposome bilayer modified liposomes sorafenib,and orthogonal design optimization of formulation and process modified liposomes to drug encapsulation efficiency,the modified liposome particle size,modified liposome targeting index (TI) changes as the evaluation index,evaluation of the modified liposomes on drug encapsulation efficiency, particle size, the impact of targeting.Results18-Gal modified sorafenib liposomes (18-GalST-LP) of the encapsulation efficiency was 65.85%, particle size (203±11) nm or so, measured by animal experiments liver targeting index (TI ) is 4.745, indicating that the 18-GalSt-LP has liver tropism. ConclusionThe formulation optimization of Stearyl alcohol derivatives Sorafenib modified liposome, high encapsulation efficiency, targeting obvious results targeted for further study of the liver provides a theoretical basis.